

Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension

SECTION 1 - IDENTIFICATION

Product Identifier: Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP

Synonyms: 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid.

9-fluoro-11(beta),17,21-trihydroxy-16(alpha)methylpregna-1,4-diene-3,20-dione

NDC Code: 72485-625-13

Recommended Use: Pharmaceutical

Manufacturer: Ophtapharm AG

Riethofstrasse 1 CH-8442 Hettlingen

Switzerland

Telephone: +1855-473-6847 **Email:** quality@sentiss.ch

SECTION 2 - HAZARD(S) IDENTIFICATION

Classification of the substance or mixture

GHS classification: Reproductive Toxicity, Category 1B, H360; May damage fertility or the

unborn child.

Hazard pictograms (GHS):

Signal word (GHS): Danger

Hazard statements (GHS): H360 - May damage fertility or the unborn child. Precautionary statements (GHS): P201 - Obtain special instructions before use.

P202 - Do not handle until all safety precautions have been read and

understood.

P280 - Wear protective gloves/protective clothing/eye protection/face

protection.

P308+P313 - If exposed or concerned: Get medical advice/attention.

P405 - Store locked up.

P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or

international regulation.

Other hazards which do not result in

classification:

No additional information available

Unknown acute toxicity (GHS_US): Not applicable

Page 1 of 8 Rev. 00/2023



Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension

SECTION 3 – COMPOSITION/INFORMATION ON INGREDIENTS

| Name Ciprofloxacin hydrochloride monohydrate (active) | Product identifier (CAS-No.) 86393-32-0 | % 0.1 - 0.5 | GHS classification Not classified |
|---|--|-----------------------|--|
| Boric acid | (CAS-No.) 10043-35-3 | 0.1-0.7 | Repr. 1B, H360 |
| Dexamethasone (active) | (CAS-No.) 50-02-2 | 0.1 - 0.5 | Eye Irrit. 2B, H320 Repr. 2, H361 STOT RE 2, H373 |

^{*}Chemical name, CAS number and/or exact concentration have been withheld as a trade secret Full text of hazard classes and H-statements: see section 16

SECTION 4 – FIRST-AID MEASURES

Description of first aid measures

General: Never give anything by mouth to an unconscious person. IF exposed or concerned: Get medical

advice/attention.

Inhalation: If inhaled and if breathing is difficult, remove victim to fresh air and keep at rest in a position

comfortable for breathing.

Skin Contact: Remove affected clothing and wash all exposed skin area with mild soap and water, followed

by warm water rinse.

Eye Contact: Rinse immediately with plenty of water. Obtain medical attention if pain, blinking or redness

oersists.

Ingestion : Rinse mouth. Do NOT induce vomiting. Get medical advice/attention if you feel unwell.

Most important symptoms and effects (acute and delayed): May damage fertility or the unborn child.

Immediate medical attention and special treatment, if necessary: Treat symptomatically.

Section 5- FIRE-FIGHTING MEASURES

Extinguishing media

Suitable extinguishing media : Use extinguishing media appropriate for surrounding fire.

Unsuitable extinguishing media : None known.

Specific hazards arising from the chemical

Fire hazard : No particular fire or explosion hazard. Reactivity : No dangerous reactions known.

Page 2 of 8 Rev. 00/2023



Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension

Special protective equipment and precautions for fire-fighters

Firefighting instructions: Use water spray or fog for cooling exposed containers. Exercise caution

when fighting any chemical fire. Prevent firefighting water from entering

the environment.

Protection during firefighting: Do not enter fire area without proper protective equipment, including

respiratory protection. Wear a self-contained breathing apparatus. Wear

fire/flame resistant/retardant clothing.

Section 6 – ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

General measures: Avoid contact with skin, eyes and clothing.

For non-emergency personnel

Protective equipment: Refer to section 8

Emergency procedures: Evacuate unnecessary personnel.

For emergency responders

Protective equipment: Refer to section 8 Emergency procedures: Ventilate area.

Environmental precautions Prevent entry to sewers and public waters.

Methods and material for containment and cleaning up

For containment Contain any spills with dikes or absorbents to prevent migration and entry

into sewers or streams.

Methods for cleaning up Soak up spills with inert solids, such as clay or diatomaceous earth as soon as

possible. Collect spillage. Store away from other materials.

See Heading 8 - Exposure control and personal protection.

Section 7 - HANDLING AND STORAGE

Precautions for safe handling

Precautions for safe handling: Wash hands and other exposed areas with mild soap and water before

eating, drinking or smoking and when leaving work. Provide good ventilation in process area to prevent formation of vapour. Do not handle until all safety precautions have been read and understood. Obtain special instructions

before use. Avoid contact with skin, eyes and clothing.

Hygiene measures: Do not eat, drink or smoke when using this product.

Conditions for safe storage, including any incompatibilities

Storage conditions: Keep only in the original container in a cool well-ventilated place. Store at

20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F).

Incompatible products: Strong acids. Strong bases

Page 3 of 8 Rev. 00/2023



Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension

Section 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Ciprofloxacin hydrochloride :

Not established.

monohydrate

Boric acid :

| ACGIH | Local name | Boric acid |
|-------|----------------------|----------------------------------|
| ACGIH | ACGIH TWA (mg/m³) | 2 mg/m³ (I - Inhalable |
| | | particulate matter) |
| ACGIH | ACGIH TWA (mg/m³) | 6 mg/m³ (I - Inhalable |
| | | particulate matter) |
| ACGIH | Remark (ACGIH) | TLV [®] Basis: URT irr. |
| | | Notations: A4 (Not |
| | | classifiable as a Human |
| | | Carcinogen) |
| ACGIH | Regulatory reference | ACGIH 2019 |

Dexamethasone : Not established.

Appropriate engineering controls

Appropriate engineering

Avoid splashing. Ensure good ventilation of the workstation.

controls

Environmental exposure

controls

Avoid release to the environment.

Individual protection measures/Personal protective equipment

Personal protective : Avoid all unnecessary exposure

equipment

Hand protection : Use rubber gloves

Eye protection : In case of splashing or aerosol production: protective goggles.

Respiratory protection : No special respiratory protection equipment is recommended under

normal conditions of use with adequate ventilation.

Other information : Do not eat, drink or smoke during use.

Page 4 of 8 Rev. 00/2023

SENTISS

MATERIAL SAFETY DATA SHEET

Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension

SECTION 9 – PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state: : Liquid

Appearance/Color : White to off-white suspension

Odor No data available Odor threshold No data available рΗ No data available Melting point No data available Freezing point No data available **Boiling point** No data available Flash point No data available Relative evaporation rate (butylacetate=1) No data available Nonflammable Flammability (solid, gas) Vapour pressure No data available Relative vapour density at 20 °C No data available Relative density No data available Solubility No data available Log Pow No data available Auto-ignition temperature No data available Decomposition temperature No data available Viscosity, kinematic No data available Viscosity, dynamic No data available **Explosive limits** No data available

Other Information : No additional information available

SECTION 10 – STABILITY AND REACTIVITY

Explosive properties

Oxidizing properties

Reactivity : No dangerous reactions known. Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Hazardous polymerization will not occur.

Conditions to avoid : None known.

Incompatible materials : Strong acids. Strong bases.

Hazardous decomposition products : None known.

Page 5 of 8 Rev. 00/2023

No data available

No data available



Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension

SECTION 11 – TOXICOLOGICAL INFORMATION

Information on toxicological effects

Acute toxicity (oral) : Not classified
Acute toxicity (dermal) : Not classified
Acute toxicity (inhalation) : Not classified

Ciprofloxacin Hydrochloride Monohydrate

LD50 oral rat > 2000 mg/kg

Boric Acid

LD50 oral rat ≥ 2660 mg/kgLD50 dermal rabbit > 2000 mg/kgLC50 inhalation rat (mg/l) > 2 mg/l/4h

Dexamethasone

LD50 oral rat > 3000 mg/kg

Skin corrosion/irritation : Not classified
Serious eye damage/irritation : Not classified
Respiratory or skin : Not classified

sensitization

Germ cell mutagenicity : Not classified Carcinogenicity : Not classified

Reproductive toxicity : May damage fertility or the unborn child.

STOT-single exposure : Not classified

STOT-repeated exposure : May cause damage to organs through prolonged or repeated exposure.

Aspiration hazard : Not classified Viscosity, kinematic : No data available

Likely routes of exposure : Inhalation. Skin and eye contact.

Symptoms/effects : May damage fertility or the unborn child.

Page 6 of 8 Rev. 00/2023



Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension

SECTION 12 - ECOLOGICAL INFORMATION

Toxicity Boric Acid

LC50 fish 1 ≥ 1.02 g/l Carassius auratus, 3 days

EC50 crustacea 658 – 875 mg/l 48 hours LOEC (chronic) > 97 mg/l salmo gairdneri

Persistence and degradability

Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension USP

Persistence and degradability : Not established.

Boric acid

Persistence and degradability : Not readily biodegradable.

Ciprofloxacin

Persistence and degradability : Not readily biodegradable.

Dexamethasone

Persistence and degradability : Readily biodegradable.

Biodegradation : > 95 %

Bioaccumulative potential

Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension USP

Bioaccumulative potential : Not established.

Boric acid

BCF fish 1 : 34 mg/l Oncorhynchus tschawytscha, 90 days at 12° C

Log Pow : -0.757 at 25 degrees C

Mobility in soil

Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension USP

Ecology - soil : Not established.

Other adverse effects: Avoid release to the environment

SECTION 13 - DISPOSAL CONSIDERATIONS

Disposal methods

Sewage disposal recommendations : Do not dispose of waste into sewer

Waste disposal recommendations : Dispose in a safe manner in accordance with local/national regulations

Ecology - waste materials : Avoid release to the environment

SECTION 14 - TRANSPORT INFORMATION

Department of Transportation (DOT)

In accordance with DOT : Not regulated Transport by sea : Not regulated Air transport : Not regulated

Page 7 of 8 Rev. 00/2023



Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension

SECTION 15 - REGULATORY INFORMATION

US Federal Regulation

Ciprofloxacin Hydrochloride Monohydrate

EPA TSCA Regulatory Flag Exempt from TSCA: Pharmaceutical/drug substance

Boric Acid

Listed on the United States TSCA (Toxic Substances Control Act) inventory

Dexamethasone

Listed on the United States TSCA (Toxic Substances Control Act) inventory

US State regulations

California Proposition 65 : This product does not contain any substances known to the state of

California to cause cancer, developmental and/or reproductive harm

SECTION 16 - OTHER INFORMATION

The information given herein is in good faith and to the best of our knowledge, but no warranty expressed or implied is made.

Revision Date: 11/07/2023 **Revision Number:** 0

Disclaimer: This document is generated to distribute health, safety and environmental data. It is not a specification sheet and none of the displayed data should be construed as a specification. Information on this MSDS sheet was obtained from sources which we believe are reliable, and we believe that the information is complete and accurate. However, the information is provided without any warranty, express or implied, regarding its correctness. Some of the information presented and conclusions drawn are from sources other than direct test data of the substance. The conditions or methods of handling, storage, use and disposal of the product are beyond our control and may also be beyond our knowledge. It is the user's responsibility to determine the suitability of any material for a specific purpose and to adopt such safety precautions as may be necessary. If the product is used as a component in another product, this MSDS information may not be applicable. For these reasons, we do not assume any responsibility and expressly disclaim liability for any loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of this product.

Page 8 of 8 Rev. 00/2023